The Association between CFTR Gene Mutation Heterozygosity and Asthma Development: A Systematic Review

Asthma is caused by complex interactions between environmental and genetic factors. Various genes have been implicated as potential risk factors in the development of asthma; among them is cystic fibrosis transmembrane conductance regulator (CFTR) gene. The aim of this systematic review was to investigate the association of CFTR mutation heterozygosity with the development of asthma, by updating the existing data with recent studies’ findings. Therefore, a systematic review of the literature was conducted on Pubmed, ESBCO (Cinahl) and Scopus Databases up to December 2022. After the eligibility assessment, 17 studies were included in this review. Nine of them supported a lack of relationship between CFTR mutation heterozygosity and asthma susceptibility, and eight reported a positive association. Consequently, more extensive research is needed through high-quality studies to provide valid evidence and highlight the clinical benefits of identifying CFTR mutations in asthma patients, their impact on asthma severity, or treatment perspectives.

[1]  S. Sciortino,et al.  CFTR gene variants, air pollution, and childhood asthma in a California Medicaid population , 2022, Pediatric pulmonology.

[2]  P. Nair,et al.  CFTR heterozygosity in severe asthma with recurrent airway infections: a retrospective review , 2022, Allergy, Asthma & Clinical Immunology.

[3]  M. Taulan-Cadars,et al.  Splicing mutations in the CFTR gene as therapeutic targets , 2022, Gene Therapy.

[4]  Fei Shi,et al.  Gene polymorphisms in asthma: a narrative review , 2022, Annals of translational medicine.

[5]  E. Mayo-Wilson,et al.  The PRISMA 2020 statement: an updated guideline for reporting systematic reviews , 2021, BMJ.

[6]  M. Baiget,et al.  Association of the CFTR gene with asthma and airway mucus hypersecretion , 2020, PloS one.

[7]  B. Nordestgaard,et al.  Morbidity and mortality in carriers of the cystic fibrosis mutation CFTR Phe508del in the general population , 2020, European Respiratory Journal.

[8]  Aaron C. Miller,et al.  Cystic fibrosis carriers are at increased risk for a wide range of cystic fibrosis-related conditions , 2019, Proceedings of the National Academy of Sciences.

[9]  H. Siala,et al.  Association of M470V polymorphism of CFTR gene with variability of clinical expression of asthma: Case-report study. , 2019, Allergologia et immunopathologia.

[10]  M. Lougheed,et al.  Severe asthma and cystic fibrosis: Overlapping phenotypes? , 2018, Canadian Journal of Respiratory, Critical Care, and Sleep Medicine.

[11]  P. Palange,et al.  Cystic fibrosis , 2016, The Lancet.

[12]  R. Dahl,et al.  Risk of asthma in heterozygous carriers for cystic fibrosis: A meta-analysis. , 2016, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[13]  A. Caspi,et al.  Methylomic markers of persistent childhood asthma: a longitudinal study of asthma-discordant monozygotic twins , 2015, Clinical Epigenetics.

[14]  S. Awasthi,et al.  Spectrum and distribution of CFTR gene mutations in asthma and chronic pancreatitis cases of North Indian population. , 2014, Gene.

[15]  S. Awasthi,et al.  CFTR Gene Mutations and Asthma in Indian Children: A Case–Control Study , 2013, Indian Journal of Clinical Biochemistry.

[16]  Hong Yin,et al.  The susceptibility of T5-TG12 of the CFTR gene in chronic bronchitis occurrence in a Chinese population in Jiangsu province, China , 2012, Journal of biomedical research.

[17]  S. Awasthi,et al.  Association of CFTR gene mutation with bronchial asthma , 2012, The Indian journal of medical research.

[18]  S. Awasthi,et al.  Association of CFTR gene mutation with bronchial asthma and its severity in Indian children: A case-control study , 2012, Annals of human biology.

[19]  Min Goo Lee,et al.  Association between Cystic Fibrosis Transmembrane Conductance Regulator Gene Mutations and Susceptibility for Childhood Asthma in Korea , 2010, Yonsei medical journal.

[20]  M. Tzetis,et al.  Asthma and pulmonary function abnormalities in heterozygotes for cystic fibrosis transmembrane regulator gene mutations. , 2008, International journal of clinical and experimental medicine.

[21]  K. Carlsen,et al.  CFTR gene mutations and asthma in the Norwegian Environment and Childhood Asthma study. , 2006, Respiratory medicine.

[22]  Daniel Y. T. Goh,et al.  Cystic fibrosis transmembrane conductance regulator (CFTR) gene mutations in Asians with chronic pulmonary disease: a pilot study. , 2006, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[23]  M. Tzetis,et al.  CFTR gene mutations – including three novel nucleotide substitutions – and haplotype background in patients with asthma, disseminated bronchiectasis and chronic obstructive pulmonary disease , 2001, Human Genetics.

[24]  C. Castellani,et al.  A pilot survey of cystic fibrosis clinical manifestations in CFTR mutation heterozygotes. , 2001, Genetic testing.

[25]  X. Estivill,et al.  CFTR and asthma in the French EGEA study , 2001, European Journal of Human Genetics.

[26]  X. Estivill,et al.  Missense mutations in the cystic fibrosis gene in adult patients with asthma , 1999, Human mutation.

[27]  A. Lowenfels,et al.  δF508 heterozygosity and asthma , 1998, The Lancet.

[28]  B. Nordestgaard,et al.  ΔF508 heterozygosity in cystic fibrosis and susceptibility to asthma , 1998, The Lancet.

[29]  Scott A. Schroeder,et al.  Protection against bronchial asthma by CFTR ΔF508 mutation: A heterozygote advantage in cystic fibrosis , 1995, Nature Medicine.